SCHEMBL4650266

SCHEMBL4650266

Nc1cc(C[C@H](NC(=O)c2ccccc2)C(=O)NCCCCc2ccccc2)ccc1OC(F)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 2/20 0.49
KMT2A Q03164 2/20 0.45
CTSL P07711 3/20 0.44
CTSS P25774 2/20 0.44
CTSK P43235 2/20 0.44
CTSB P07858 2/20 0.44
CTSV O60911 1/20 0.44
MAPT P10636 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 2/20 0.44
MEN1 O00255 1/20 0.44
PTPN1 P18031 1/20 0.43
SRC P12931 1/20 0.42
CHRNA1 P02708 1/20 0.42
CHRNG P07510 1/20 0.42
CHRNB1 P11230 1/20 0.42
CHRND Q07001 1/20 0.42
ALDH1A1 P00352 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7047071 0.90 GRIA1 (0.54) GRIA1PTPN1SRCCHRNA1CHRNG
SCHEMBL7048811 0.90 CHRNA1 (0.53) GRIA1CTSLPTPN1SRCCHRNA1
SCHEMBL4650909 0.86 PTPN1 (0.55) GRIA1KMT2ACTSLCTSSCTSK
SCHEMBL4651088 0.85 MAPT (0.43) KMT2AMAPTL3MBTL1LMNAMEN1
SCHEMBL7054281 0.85 CHRNB2 (0.49) GRIA1CTSLCTSSCTSKCTSV
SCHEMBL4651118 0.84 ITGB3 (0.42) GRIA1KMT2AMAPTL3MBTL1LMNA
SCHEMBL4650233 0.84 ITGB3 (0.48) KMT2AMAPTL3MBTL1LMNAMEN1
SCHEMBL4650264 0.81 NPY5R (0.52) MAPTLMNA
SCHEMBL4650222 0.81 ITGB3 (0.53) MAPTL3MBTL1PTPN1ALDH1A1
SCHEMBL7114722 0.81 ITGB3 (0.53) MAPTL3MBTL1PTPN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1301474-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS Array Biopharma Inc. (US) 2003-04-16 EP claimed
US-20020040003-A1 Preparation of phosphatase inhibitors ARRAY BIOPHARMA INC. 2002-04-04 US claimed
WO-2002004412-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2002-01-17 WO claimed
EP-1301474-B1 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC (US) 2008-09-10 EP disclosed
US-6586467-B2 Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus ARRAY BIOPHARMA INC. 2003-07-01 US disclosed
EP-1301474-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS Array Biopharma Inc. (US) 2003-04-16 EP disclosed
US-20020040003-A1 Preparation of phosphatase inhibitors ARRAY BIOPHARMA INC. 2002-04-04 US disclosed
WO-2002004412-A2 TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040003-A1 Preparation of phosphatase inhibitors PTPRS, PTPRO, PTPRR GRIA1 2535/4885KMT2A 3124/4885CTSL 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.